{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:21:45Z","timestamp":1755796905050,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The Second Hospital of Shanxi Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"DOI":"10.1007\/s40744-022-00496-z","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:24:31Z","timestamp":1669706671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report"],"prefix":"10.1007","author":[{"given":"Ye","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3954-1819","authenticated-orcid":false,"given":"Jinli","family":"Ru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"9","key":"496_CR1","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/1756-185X.13649","volume":"22","author":"K Barut","year":"2019","unstructured":"Barut K, Adrovic A, Sahin S, et\u00a0al. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience. Int J Rheum Dis. 2019;22(9):1661\u20139.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"496_CR2","first-page":"146","volume":"36","author":"A Adrovic","year":"2020","unstructured":"Adrovic A, Yildiz M, K\u00f6ker O, \u015eahin S, Barut K, Kasap\u00e7opur \u00d6. Biologics in juvenile idiopathic arthritis\u2014main advantages and major challenges: a narrative review. Arch Rheumatol. 2020;36(1):146\u201357.","journal-title":"Arch Rheumatol"},{"key":"496_CR3","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, et\u00a0al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77:819\u201328.","journal-title":"Ann Rheum Dis"},{"key":"496_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","volume":"104","author":"Gadina Massimo","year":"2018","unstructured":"Massimo Gadina, Catrina Johnson, Daniella Schwartz, et\u00a0al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J Leukoc Biol. 2018;104:499\u2013514.","journal-title":"J Leukoc Biol"},{"issue":"10315","key":"496_CR5","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, et\u00a0al. Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):1984\u201396.","journal-title":"Lancet."},{"issue":"5","key":"496_CR6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-2845","volume":"143","author":"Z Huang","year":"2019","unstructured":"Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. 2019;143(5): e20182845.","journal-title":"Pediatrics"},{"issue":"1","key":"496_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clim.2015.04.018","volume":"159","author":"N Bruck","year":"2015","unstructured":"Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (SJIA) and target-directed therapeutic approaches. Clin Immunol. 2015;159(1):72\u201383.","journal-title":"Clin Immunol"},{"key":"496_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et\u00a0al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395.","journal-title":"N Engl J Med"},{"issue":"1","key":"496_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12969-018-0236-y","volume":"16","author":"M Bielak","year":"2018","unstructured":"Bielak M, Husmann E, Weyandt N, et\u00a0al. IL-6 blockade in systemic juvenile idiopathic arthritis\u2014achievement of inactive disease and remission (data from the German AID-registry). Pediatr Rheumatol Online J. 2018;16(1):22.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"8","key":"496_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/RHU.0000000000000456","volume":"22","author":"B Tseng","year":"2016","unstructured":"Tseng B, Amighi A, Bradford K, Wang HL, Getzug TE, Brahn E. Tofacitinib response in juvenile idiopathic arthritis (JIA) and collagenous colitis. J Clin Rheumatol. 2016;22(8):446\u20138.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"496_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12887-021-02494-6","volume":"21","author":"V Vuki\u0107","year":"2021","unstructured":"Vuki\u0107 V, Smajo A, Vidovi\u0107 M, Vukojevi\u0107 R, Harja\u010dek M, Lamot L. Beyond the guidelines management of juvenile idiopathic arthritis: a case report of a girl with polyarticular disease refractory to multiple treatment options and Leri Weill syndrome. BMC Pediatr. 2021;21(1):40.","journal-title":"BMC Pediatr"},{"issue":"3","key":"496_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","volume":"39","author":"E Miserocchi","year":"2020","unstructured":"Miserocchi E, Giuffr\u00e8 C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847\u201351.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"496_CR13","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, et\u00a0al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959\u201364.","journal-title":"Blood"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00496-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00496-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00496-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T15:31:27Z","timestamp":1669735887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00496-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":13,"alternative-id":["496"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00496-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}